Histogenics Corp (NASDAQ: HSGX) shares were down 73% of their market value at time of publishing following the release data of its Phase 3 clinical trial of NeoCart that did not meet the primary endpoint of a statistically significant improvement in pain and function in a dual threshold responder analysis one year after treatment as […]